ECOG PCO-RL: E2205 SA: A Randomized Phase II Study to Measure Response Rate and Toxicity of Neo-Adjuvant Chemoradiotherapy with Oxaliplatin (OX) and Infusional 5-Fluorouracil (5-FU) Plus Cetuximab Followed by Post-Operative Docetaxel and Cetuximab in Pat

Project: Research project

Project Details

Effective start/end date6/9/086/8/15


  • Frontier Science and Technology Research Foundation (PCOE2205SA-00//E2205)
  • Sanofi US Services Inc. (PCOE2205SA-00//E2205)